Panel, Roundtable
The Search for Cures Leads to Silicon Valley
Milken InstituteLindy Fishburne, Linda Avey, Noah Craft, Lloyd Minor, Asha Nayak, Lisa Suennen, Asha Rogers, Martha Minow, Male Speaker 2, Brody
- The panel is scheduled to conclude within 45 minutes to accommodate 10 to 15 minutes for questions.
- Intel aims to enable personalized medicine initially focused on cancer care, with the goal of matching treatments to specific tumors and side effect profiles, while planning to expand the Collaborative Cancer Cloud platform to address Alzheimer's and cardiovascular diseases.
- Stanford projects that a decade from now, earlier diagnosis and prevention will reduce the need for complex treatments and increase patient engagement.
- Science 37 plans to accelerate drug discovery by decentralizing clinical trials, achieving a model 30 to 40% faster than traditional methods, with a specific trial involving 400 patients across eight states launching next month without in-person meetings.
- Science 37 intends to launch an oncology trial in California soon to ship drugs to patients with solid tumors and manage the trial remotely, and previously launched a trial for a live bacterial drug involving 400 patients across eight states.
- Behavioral science is expected to play a critical role in treatment compliance, with predictions that data delivered in real time at the bedside could significantly reduce the current estimated 33% waste or error rate in medical care.
- The Intel St. John's sepsis agent tool has already predicted to save over 2,700 lives through early detection in recent months, while Parkinson's treatment regimens are beginning to be custom-titrated using data from Pebble Watches and specific algorithms.
- The American Heart Association is establishing a cardiovascular precision medicine Institute to generate knowledge for clinicians and researchers.
- A joint venture including Dignity Health, United Healthcare, and Baylor plans to use central analysis to identify the most cost-effective medical devices with the least negative side effects.
- Emerging companies like HealthReveal intend to use algorithms to predict issues such as strokes and provide prescriptive medicine at the point of care, mirroring an analytical power and human oversight model similar to that used by PayPal.
- Healthcare systems are expected to gain monetization value through bundled payments and outcomes-based reimbursement models that validate better health outcomes.
- While HIPAA is not expected to be a significant barrier for tech companies, doctor-to-doctor information sharing remains a difficult system issue to resolve.
- Telemedicine is projected to reduce the necessity of visits to major centers like MD Anderson for routine follow-ups, with primary care physicians available until 11 p.m.
- Innovation in the pharmaceutical sector requires a reimbursement model that extends beyond one-year budget cycles, as investment returns often take two years or more to materialize.
- Mobile applications are predicted to be effective only within an interoperable ecosystem where EMRs communicate, with a specific five-year timeframe noted for resolving this interoperability issue.
- Patient weariness regarding participation incentives is expected due to a perceived lack of clear return on investment, despite the emergence of such incentives.
- Health engagement is anticipated to undergo a revolution in the coming decade, supported by the projection that 80% of adults globally will have smartphone access by 2020.
- Large longitudinal studies are expected to correct dilemmas arising from past medical recommendations based on inadequate data or flawed analyses.